All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11320%2F13%3A10144237" target="_blank" >RIV/00216208:11320/13:10144237 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/13:10144237 RIV/00064165:_____/13:10144237

  • Result on the web

    <a href="http://www.ecco-jccjournal.org/article/S1873-9946(12)00456-4/abstract" target="_blank" >http://www.ecco-jccjournal.org/article/S1873-9946(12)00456-4/abstract</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.crohns.2012.10.019" target="_blank" >10.1016/j.crohns.2012.10.019</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

  • Original language description

    Background and aims: Over 10% of Crohn's disease (CD) patients annually lose response to infliximab. Infliximab trough levels (TL), concomitant immunosuppressants and endoscopic healing were proposed as predictors of favourable infliximab outcome. We assessed infliximab TL measured after induction therapy as predictors of sustained clinical response. Furthermore, we tried to identify other predictors of long-term benefit of infliximab therapy. Methods: We included CD patients treated with infliximab between October 2007 and March 2010 who responded to 3-dose induction followed by maintenance therapy and in whom blood samples taken at treatment week 14 or 22 were available in blood bank. Sustained response to infliximab was defined as absence of treatment failure due to loss of response or drug intolerance. Results: Eighty four patients were included. Sustained response to infliximab was observed in 47 (56%) patients during a median follow-up of 25 months (14-37). lnfliximab TL>3 mu g/m

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    BB - Applied statistics, operational research

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2013

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of Crohn's and Colitis

  • ISSN

    1873-9946

  • e-ISSN

  • Volume of the periodical

    7

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    NL - THE KINGDOM OF THE NETHERLANDS

  • Number of pages

    8

  • Pages from-to

    736-743

  • UT code for WoS article

    000323995900007

  • EID of the result in the Scopus database